---

Biomarkers are deeply incorporated into up-to-date clinical guidelines for acute, acutely decompensated and chronic heart failure. According to contemporary evaluation of efficacy of medical care in disease management, cardiac biomarkers are recognized an individual probes that are suitable for stratification of individuals at risk of hea development and progression, improving heart failure prevention, and target-to-treat heart failure therapy. There is a large body of evidence regarding the limiting role of biomarker as predictive tool in heart failure management. Lots of sophisticated biomarker predictive scores have now created to attenuate heart failure risk prognostication, there was not received strong evidence that all these are equal on their ability to predict clinical outcomes and death in patients with different phenotypes of HF, across all pathophysiological stages of heart failure, at acute and chronic HF and even in heart failure patients with several co-morbidities, various ages and ethnicities.

---

Alexander E. Berezin is currently Professor (full)of Medicine, Senior Consultant of Cardiology Unit of InternalMedicine Department at State Medical University, Zaporozhye, Ukraine.His research goals are fundamental study of biological markers, thedevelopment of cardiovascular prevention and rehabilitation. Based onthis research and training in heart failure he has received severalawards and honors. He has published 950 papers and more in reputedjournals, 43 books/chapters and has been serving as an editorialboard member of repute.

---